PPI

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
torsdag, maj 9, 2024
Vonoprazan/amoxicillin, Table, FDA, DTC, Pharmacy, Gastrointestinal disease, NERD, NDA, Hercules, Amazon Prime Video, Food, Research, Webcast, Business, Forecasting, Prescription, Cigna, PPI, PDUFA, Tablet, Patient, Physician, Ratio, Enzyme inhibitor, DDW, Marketing, Vonoprazan/amoxicillin/clarithromycin, Heartburn, Hulu, GERD, Clinical trial, GAAP, Growth, Overalls, Eosinophilic esophagitis, Pharmaceutical industry

ET

Key Points: 
  • ET
    FLORHAM PARK, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter of 2024, and provided recent business highlights.
  • A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below.
  • Phathom will host a conference call and webcast to discuss its first quarter financial results and business highlights today, May 9, 2024, at 8:30 a.m.
  • Phathom believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding Phathom's results of operations.

Schwab Trading Activity Index™: Score Declines to Moderate-Low Levels in April Amid Market Volatility

Retrieved on: 
måndag, maj 6, 2024
Professional Services, Finance, Asset Management, Fintech, Consulting, Banking, Personal Finance, Consumer, VIX, PPI, Treasury, Schwab, PCE, Dow Jones Industrial Average, CPI, STAX, Federal Reserve, Activity, Unemployment, Labour, Current Population Survey, Multimedia, Nasdaq Composite, Producer, CBOE, Financial adviser

The Schwab Trading Activity Index™ (STAX) decreased to 48.87 in April, down from its score of 51.65 in March.

Key Points: 
  • The Schwab Trading Activity Index™ (STAX) decreased to 48.87 in April, down from its score of 51.65 in March.
  • “While Schwab clients were net buyers of equities, the investor enthusiasm that characterized the March results began to wane in April, pushing down the STAX score for the month.
  • The CBOE Volatility Index (VIX) spiked from 13.01 to 15.03, reflecting additional perceived downside risks to equities.
  • Popular names bought by Schwab clients during the period included:
    Names net sold by Schwab clients during the period included:

PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA

Retrieved on: 
måndag, april 29, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Pathfinder, Bone marrow, PPI, Nature Biomedical Engineering, BCL2, SPID, Proteomics, Collection, Seoul National University, AML, Prescription, Disease, Family, Acute myeloid leukemia, Patient, Interaction, Biology, Biomarker, Drug development, Medical device

PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx.

Key Points: 
  • PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx.
  • Starting in May, PROTEINA will transport its Pi-View analysis device and related reagents to labs at Emory.
  • PROTEINA and Dr. Woo’s research team will analyze these samples using the PPI PathFinder BCL2 Dx to validate its clinical efficacy.
  • PROTEINA’s CEO, Tae-Young Yoon, remarked, “Having successfully completed domestic clinical validation in South Korea over the past two years, we are very excited about this large-scale clinical validation in the United States.

PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono

Retrieved on: 
torsdag, april 25, 2024
Dai, ONO, PPI, Drug discovery, PRISM, Patient, Discovery, History, Pharmaceutical industry

TOKYO, April 25, 2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and licensing agreement with ONO PHARMACEUTICAL CO., LTD. ("Ono ").

Key Points: 
  • Under the terms of the agreement, Ono and PRISM will jointly create a development candidate for Ono's oncology target using PepMetics® technology.
  • Upon identification of the development candidate, PRISM will license its rights to Ono for clinical development and commercialization.
  • "We highly appreciate PRISM's PepMetics® technology in PPI drug discovery", said Seishi Katsumata, Executive Director, Discovery & Research of Ono.
  • "We are very excited to enter into this collaboration with Ono who has a history of creating innovative drugs.

Nowcasting consumer price inflation using high-frequency scanner data: evidence from Germany

Retrieved on: 
tisdag, april 23, 2024
Consensus, Online, Cream, Honey, Tax, Glass, MAPI, Consensus Economics, Journal of Economic Perspectives, Milk, Shower, Low-alcohol beer, Autoregressive–moving-average model, Infant, C3, Islam, Wine, Core inflation, Research Papers in Economics, National accounts, Kálmán, Barcode, Journal of International Economics, Communication, Royal Statistical Society, COVID19, Kohl (cosmetics), Natural disaster, Business, Observation, Paper, VAT, European Economic Review, Diebold Nixdorf, Blancmange, Calendar, Sunflower oil, Annual Review of Economics, Hand, C4, DESTATIS, NBER, Tinning, Razor, Forecasting, Gasoline, Coffee, European Economic Association, Cat, Journal of Monetary Economics, Journal of Applied Econometrics, Medeiros, Architecture, Oxford University Press, Producer, GfK, Quarterly Journal of Economics, Margarine, NCBS, Starch, Political economy, Consistency, COVID-19, Consensus decision-making, Website, MIDAS, Behavior, Deutsche Bundesbank, PPI, World Bank, Collection, Medical classification, Orange, Eurozone, Butter, FMCG, Noise, Travel, Clothing, History, Inflation, Liver, International economics, Journal of Political Economy, BSI, OLS, Statistics, Consumer, PDF, University of Chicago, Classification, ECB, Fats, Policy, Multi, WOB, Outline, C6, Mincing, Canadian International Council, Social science, Perfume, University of California, Berkeley, Journal of Forecasting, Federal Reserve Bank, JEL, L1, Journal, Research, Candle, Food, TPD, Credit, Spice, LPG, Janssen, Marmalade, Superior, Literature, Chocolate, Beef, Kiel University, European Central Bank, Natural gas, HICP, Monetary economics, Yogurt, Section 5, ILO, Bermingham, Price, GTIN, Cheese, Macroeconomics, Growth, Beck, XJ, Government, De Beer, Supermarket, Ice cream, Naturally, C53, Corn flakes, BIS, Biscuit, LASSO, Petroleum, A.2, Poultry, Accuracy and precision, Application, White, Lettuce, Risk, ESCB, University of Siegen, OECD, Chapter One, Lipstick, Sack, XT, BIC, Garlic, Consumption, Sokol, Meat, VAR, Database, Section 3, Rusk, American Economic Journal, Royal, Curd, Overalls, Lamb, Great Lockdown, Fruit, Economy, COICOP, International Journal of Forecasting, Aftershave, Section 2, Nonparametric statistics, Attention, Conference, CPI, Heat, Public economics, Common sunflower, Nowcasting, American Economic Review, Computational Statistics (journal), GFK, COVID-19 pandemic, Exercise, Shock, Running, UNECE, Edible, Gambling, Banco, Rigid transformation, European Commission, Frozen, C.2, PRISMA, Official statistics, Concept, Drink, Transaction data, Somatosensory system, Punctuality, Altbier, Food prices, Response, GDP, Index, E31, Cabinet of Germany, Holiday, Machine learning, Series, Green, Whisky, Vegetable, Cola, Journal of Econometrics, Sadik Harchaoui, University, Aggregate, World Bank Group, B.1, Use, Book, Economic statistics, Civil service commission, 1L, Apple, Bread, Filter, Central bank, Brandeis University, Economic Modelling, Bank, Barkan, Roulade, Dairy product, Neural network, Reproduction, IMF, Section, ID, Data, D4L, Cryptocurrency
Key Points: 

    Rapafusyn Announces Multiple Presentations at the 2024 Drug Discovery Chemistry Conference

    Retrieved on: 
    måndag, april 1, 2024
    Poster, Emerging technologies, Conference, PPI, Pharmaceutical industry

    BALTIMORE, April 01, 2024 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals is pleased to announce two upcoming presentations at Cambridge Health Institute’s 12th Annual Oral Peptides & Macrocyclics Conference, April 1 – 4 in San Diego.

    Key Points: 
    • BALTIMORE, April 01, 2024 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals is pleased to announce two upcoming presentations at Cambridge Health Institute’s 12th Annual Oral Peptides & Macrocyclics Conference, April 1 – 4 in San Diego.
    • Dr. Rick Ewing, VP and Head of Chemistry, will be giving an oral presentation on Rapafusyn’s Non-Degradation Molecular Glue platform.
    • Dr. Sam Hong, Sr. Director and Head of Platform, will be presenting a poster on Rapafusyn’s industry-leading libraries of molecular glues.
    • We are excited to share our efforts at the Oral Peptides and Macrocyclics Conference” said Dr. Sean Hu, CEO of Rapafusyn.

    Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

    Retrieved on: 
    tisdag, mars 26, 2024
    Connected, HIV-1, Amazon Prime Video, Breast milk, Face, Hypoesthesia, Patient, Chronic pain, Clostridioides, Heartburn, Lymph, Magnesium, Diarrhea, Myalgia, Spine, Allergy, Muscle weakness, Vonoprazan, Stomach, Vitamin, Dizziness, Potassium, Hip, Risk, Tongue, Chills, DTC, Safety, Food, PPI, Rash, Food and Drug Administration, GERD, Enzyme inhibitor, Skin, Esophagitis, HIV, Rilpivirine, Kidney, FDA, Esophagus, B-12, Weakness, Infection, Indigestion, Smart TV, Seizure, Inflammation, Polyp, Calcium, Extrapyramidal system, Bone fracture, Nausea, Spasm, Urine, Fever, Clostridioides difficile, Bleeding, Blood, Wrist, Blister, Vitamin B12, Human, Medicine, Pharmaceutical industry

    FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. VOQUEZNA (vonoprazan) is indicated for the healing and maintenance of healing of all severities of Erosive Esophagitis (EE), also referred to as Erosive GERD, and for the relief of related heartburn. VOQUEZNA represents the first major innovation to the U.S. Erosive GERD market in over 30 years.1

    Key Points: 
    • The campaign will also be featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads.
    • “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day.
    • To view a video of the “VOQUEZNA Can Kick Some Acid” commercial, click here.
    • Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

    Schwab Trading Activity Index™: Score Ascends to Moderate Levels in March

    Retrieved on: 
    måndag, april 8, 2024
    Professional Services, Business, Finance, Fintech, Asset Management, Banking, Consumer, Education, CPI, VIX, Labour, Federal Reserve, Name, STAX, S&P, Activity, Current Population Survey, Fed, PPI, Producer, Multimedia, Treasury, Consumer confidence, CBOE, Financial adviser

    The Schwab Trading Activity Index™ (STAX) increased to 51.65 in March, up from its score of 47.65 in February.

    Key Points: 
    • The Schwab Trading Activity Index™ (STAX) increased to 51.65 in March, up from its score of 47.65 in February.
    • View the full release here: https://www.businesswire.com/news/home/20240408112995/en/
      Schwab Trading Activity Index March 2024 (Graphic: Charles Schwab)
      The reading for the four-week period ending March 28, 2024 ranks “moderate” compared to historic averages and marks the highest reading since May 2022.
    • “In the face of undeniably mixed macroeconomic data, the markets soared this month, and the STAX score continued its rise in step,” said Joe Mazzola, Director of Trading and Education at Charles Schwab.
    • “Despite the market highs, however, Schwab clients remain in the moderate range of market exposure as measured by the STAX.

    nubia Flip 5G: The Epitome of Innovation in Foldable Smartphone Technology

    Retrieved on: 
    tisdag, april 9, 2024
    EST, Smartphone, Sunshine 1530, Intelligence, HKT, 3D, Photography, DV, PPI, Creativity, Pet, Multimedia, Weather

    SHENZHEN, China, April 9, 2024 /PRNewswire/ -- nubia, a leading global smartphone manufacturer and a pioneer in innovative smartphone technology, proudly announces the launch of its groundbreaking flagship foldable smartphone, the nubia Flip 5G.

    Key Points: 
    • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- nubia, a leading global smartphone manufacturer and a pioneer in innovative smartphone technology, proudly announces the launch of its groundbreaking flagship foldable smartphone, the nubia Flip 5G.
    • Tailored specifically for the younger generation, the nubia Flip 5G  fuses together cutting-edge design and powerful functionality, posed to redefine the smartphone experience.
    • The nubia Flip 5G represents a quantum leap forward in the evolution of foldable smartphones, embodying the perfect synergy of style, innovation, and intelligence.
    • nubia is pleased to announce the pricing and availability details for the eagerly awaited nubia Flip 5G in global markets.

    Gastrointestinal Therapeutics and Diagnostics Technologies and Global Markets Report 2024-2028: Growing Trend toward Screening and Preventive Care and Adoption and Approval of Biological Drugs - ResearchAndMarkets.com

    Retrieved on: 
    fredag, april 5, 2024
    Biotechnology, Pharmaceutical, Health, Medical Devices, Sanofi, Growth, Prevalence, AbbVie, Environment, Laxative, Incidence, Antacid, ESG, Gastroesophageal reflux disease, Malignancy, Constipation, Diarrhea, GI, GERD, Irritable bowel syndrome, Prescription, Inflammatory Bowel Diseases, Gastrointestinal disease, OTC, Therapy, Pancreatitis, IBS, Endoscopy, USD, PPI

    The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

    Key Points: 
    • The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
    • The Global Gastrointestinal Therapeutics and Diagnostics Market was valued at USD 86 Billion in 2023, and is expected to reach USD 122.5 Billion by 2028, rising at a CAGR of 7.30%.
    • This research study analyzes the GI diagnostics and therapeutics market, offers revenue forecasts, assesses future trends and provides strategic recommendations for the success of market participants.
    • This report estimates market data for 2022 (the base year) and forecasts for 2023 through 2028.